iiinova — where your digital self keeps evolving

The PCCTC @thepcctc.bsky.social · 29/07/2026

Just Published: Recruitment strategies in the PCCTC-managed PROMISE Registry, an examination of the effectiveness of different recruitment strategies, including institutional partnerships, direct-to-patient marketing outreach, and community engagement grants www.sciencedirect.com/science/arti...

000

The PCCTC @thepcctc.bsky.social · 29/05/2026

Dr Tanya B. Dorff has been selected to present the PCCTC multicenter phase 1 first-in-human study evaluating the first-in-class PSMA/STEAP1 dual-targeting antibody drug conjugate ABBV-969 in patients with mCRPC during the Rapid Oral Abstract Session at #ASCO26 www.asco.org/abstracts-pr...

010

The PCCTC @thepcctc.bsky.social · 28/05/2026

The PCCTC is proud to highlight that our colleague and dear friend Mary-Ellen Taplin, MD, FASCO has been selected to present at the Plenary Session at #ASCO26 where she will present the final analysis of the PROTEUS phase 3 study www.asco.org/abstracts-pr...

010

The PCCTC @thepcctc.bsky.social · 27/05/2026

PCCTC Investigator Andrew J. Armstrong, MD, MS Selected for Rapid Oral Abstract Session at #ASCO26: www.linkedin.com/pulse/pcctc-...

000

The PCCTC @thepcctc.bsky.social · 22/05/2026

#ASCO26 abstracts are now live and we are pleased to announce 13 prostate cancer abstracts representing PCCTC science spanning radioligand therapies, PARP inhibition, immunotherapy, biomarker-driven design, NEPC, and health equity will be presented!

13 abstracts representing PCCTC science spanning radioligand therapies, PARP inhibition, immunotherapy, biomarker-driven design, NEPC, and health equity

010

The PCCTC @thepcctc.bsky.social · 15/05/2026

Results of the Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE) led by the PCCTC’s Dr. Rana McKay published in JCO: ascopubs.org/doi/pdf/10.1...

Olaparib plus radium-223 significantly prolonged rPFS compared with radium-223 in men with mCRPC and BM. Despite increased hematologic toxicity, the regimen was manageable and supports further exploration of DNA damage–targeted strategies in this population.

000

The PCCTC @thepcctc.bsky.social · 26/02/2026

Just published! Prostate Cancer Working Group 4 recommendations are now available in the Journal of Clinical Oncology, providing updated standards for clinical trial design, patient eligibility, and outcome measures in advanced prostate cancer: ascopubs.org/doi/pdfdirec...

000

The PCCTC @thepcctc.bsky.social · 25/02/2026

We’re excited to highlight the groundbreaking research being shared tomorrow by PCCTC investigators at #GU26! From cutting-edge clinical trial results to revised PCWG4 guidelines, these abstracts showcase the passion and progress driving the future of prostate cancer care.

000

The PCCTC @thepcctc.bsky.social · 28/01/2026

In an effort by PCCTC investigators and colleagues, the importance of racial diversity in future genomic profiling and clinical trials efforts is highlighted. Full manuscript: pmc.ncbi.nlm.nih.gov/articles/PMC...

000

The PCCTC @thepcctc.bsky.social · 24/10/2025

The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...

021

The PCCTC @thepcctc.bsky.social · 18/07/2025

Learn more about the PCCTC-managed PROMISE, a registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes: www.prostatecancerpromise.org

010

The PCCTC @thepcctc.bsky.social · 03/06/2025

PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!

041

The PCCTC @thepcctc.bsky.social · 02/06/2025

Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!

000

The PCCTC @thepcctc.bsky.social · 01/06/2025

Today at #ASCO25, Rapid Oral Sessions featuring PCCTC #prostatecancer science: the phase 2 Metacure trial, the novel B7H3 ADC DB‑1311/BNT324, and the phase 1 study results of JNJ-78278343

020

The PCCTC @thepcctc.bsky.social · 28/05/2025

#ASCO25 is just days away. Be sure to check out the innovative PCCTC prostate cancer clinical research presented at this year's annual meeting in Chicago!

The Prostate Cancer Clinical Trials Consortium at ASCO 2025: Abstracts Listing

020

The PCCTC @thepcctc.bsky.social · 22/05/2025

We are excited to announce science from innovative PCCTC multi-center prostate cancer studies will be represented by 16 abstracts at #ASCO25!

The PCCTC at ASCO25: Oral Abstract Sessions
3 June | Hall D1 | Live Stream
#5002: Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry..
Presenter: Michael Ong, MD, BSc, FRCPC (The Ottawa Hospital Cancer Centre)
10:33 AM – 10:45 AM CDT
#5007: A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.
Presenter: Rana R. McKay, MD, FASCO (University of California San Diego)
11:57 AM – 12:09 PM CDT

The PCCTC at ASCO25: Rapid Oral Abstract Sessions
1 June | Hall D2 | Live Stream
#5014: Intensified hormonal blockade with SBRT in PSMA-PET detected oligometastatic prostate adenocarcinoma: Results from the phase II Metacure trial cohorts B2 and the B2 expansion.
Presenter: Eric Huttenlocher Bent, MD, PhD (MSK)
4:42 PM – 4:48 PM CDT
#5015: DB‑1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
Presenter: Andrew Ohyama Parsonson, FRACP, MBBS (Macquarie University)
5:00 PM – 5:06 PM CDT
#5017: Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Capucine Baldini, MD, PhD (Institut Gustave Roussy)
5:12 PM – 5:18 PM CDT

The PCCTC at ASCO25: Poster Sessions
Gupta S, et al. Does cytoplasmic AR-V7 circulating tumor cell (CTC) detection add utility in predicting AR pathway inhibitor benefit in men with mCRPC? A retrospective analysis of the PROPHECY study. Abstract # 5043, Poster Bd # 242.
Von Amsberg G, et al. Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC). Abstract # 5059, Poster Bd #258.
Marulanda Corzo V, et al. PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes. Abstract # 5070, Poster Bd # 269.
Bryce A, et al. Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC). Abstract # 5071, Poster Bd # 270.
Attwell M, et al. A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC). Abstract # TPS5123, Poster Bd # 315b.
Wise D, et al. Phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC). Abstract # 5067, Poster Bd #266.
Johnson G, et al. SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer. Abstract # TPS5125, Poster Bd # 316b.

The PCCTC at ASCO25: Publication Only Abstracts
Sokolova A, et al. Barriers to germline genetic testing in advanced prostate cancer: Survey results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium (PCCTC). Abstract # e17073.
George D, et al. Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study. Abstract # e17076.
Schweizer M, et al. Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic (PD) markers and tumor gene expression by mevrometostat in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC). Abstract # e17032.
Alonso Gordoa T, et al. Mevrometostat, an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study. Abstract # e17029.

010

The PCCTC @thepcctc.bsky.social · 02/05/2025

Just published: PCCTC study of Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer by Dr Karen A Autio and colleagues: pmc.ncbi.nlm.nih.gov/articles/PMC...

Cover page of Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer

000

The PCCTC @thepcctc.bsky.social · 01/05/2025

Just Published: PCCTC leadership and colleagues release recommended clinical context and patient context data elements for liquid biopsy data submitted to data repositories and data commons (Clin Transl Sci): pmc.ncbi.nlm.nih.gov/articles/PMC...

Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons: In 2020, BLOODPAC recommended 11 pre-analytical minimal technical data elements for collection and submission of liquid biopsy data to public databases. This article expands on that work by recommending 22 clinical context and 10 patient context data elements. These elements, essential for liquid biopsy data submitted to repositories like the BLOODPAC Data Commons, cover tumor characteristics, disease progression, and patient demographics, supporting biomarker validation, research, and clinical trials.

000

The PCCTC @thepcctc.bsky.social · 25/04/2025

Congratulations, Howard I. Scher, MD, recipient of the Urology Care Foundation's Richard D. Williams, MD Prostate Cancer Research Excellence Award!

Howard Scher, MD
Head, Biomarker Development Program
Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College
I am most honored to be the 2025 recipient of the Urology Care Foundation (UCF) Richard D. Williams, MD Prostate Cancer Research Excellence Award, and for the Society of Urologic Oncology and UCF for recognizing the transformative effect of co-developing innovative therapeutics along with biomarkers to better inform medical decision making and improve patient outcomes. The successful execution of this strategy was made possible by the mission-driven, multidisciplinary, multi-center collaborations established by the Prostate Cancer Clinical Trials Consortium (PCCTC), a program enabled by the Prostate Cancer Foundation (PCF) and the Prostate Cancer Research Program (PCRP) of the US Department of Defense (DOD), that I had the privilege to lead which to date has provided over 16,200 patients access to clinical trials of potentially breakthrough therapies, including those for patients with disease for which no life-prolonging therapeutic options exist. I would like to thank Howard Soule from the PCF and Jake Vinson from the PCCTC in achieving these successes. I am humbled by this honor and would like to thank the prostate cancer research community, study participants, and many advocates who have made these advances possible.

000

The PCCTC @thepcctc.bsky.social · 25/04/2025

#AACR25: Two proffered abstracts detailing the PCCTC-managed International Registry for Men With Advanced Prostate Cancer (IRONMAN) are featured at this year's AACR Annual Meeting www.aacr.org/meeting/aacr...

Two proffered abstracts detailing the PCCTC-managed International Registry for Men With Advanced Prostate Cancer (IRONMAN) featured at the 2025 AACR Annual Meeting (Abstract 3630 and Abstract 4935)

010

The PCCTC @thepcctc.bsky.social · 24/04/2025

Cancer Centers Survivorship Research Forum 2025: Join our colleagues at Dana-Farber Cancer Center for two impactful days of connection, collaboration, and cutting-edge insights in survivorship research! www.eventbrite.com/e/cancer-cen...

The 3rd Biennial National Cancer Centers Survivorship Research Forum. September 18 | 9:00 AM – September 19 | 4:30 PM EDT. Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA

Hosted by Dana-Farber Cancer Institute in Boston, Massachusetts, this premier event brings together leading researchers, healthcare professionals, and advocates to explore the latest advancements in cancer survivorship research.
Engage in thought-provoking discussions, gain insights from top experts, and connect with peers dedicated to improving the care and well-being of cancer survivors.

000

The PCCTC @thepcctc.bsky.social · 14/04/2025

Relationship Between Undetectable PSA Nadir and Outcomes for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in the PCCTC-managed International Registry for Men with Advanced Prostate Cancer (IRONMAN), via UroToday: www.urotoday.com/conference-h...

Percentage of patients in each treatment group with disease relapse at months 12, 24, and 36 of treatment, stratified by PSA status at Month 6. With a median follow-up of 18 months, 291 patients (21%) experienced disease relapse, and 19% experienced PSA progression.

000

The PCCTC @thepcctc.bsky.social · 03/04/2025

PCCTC investigators publish encouraging results from their phase 1 study of FOR46, a fully human antibody conjugated to monomethyl auristatin E, in metastatic castration-resistant prostate cancer: ascopubs.org/doi/pdfdirec...

Manuscript cover for "Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant
Prostate Cancer" from the Journal of Clinical Oncology

010

The PCCTC @thepcctc.bsky.social · 01/04/2025

PCCTC investigators and colleagues identify factors associated with successful genetic testing of bone tissue for patients with metastatic prostate cancer (Eur Urol Oncol. 2025 Apr;8(2):355-363): www.sciencedirect.com/science/arti...

Manuscript cover page of "Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer" published in European Urology Oncology

020

The PCCTC @thepcctc.bsky.social · 11/03/2025

BREAKING: A vote is scheduled for today on a CR extension bill that includes a 57% cut to the Congressionally Directed Medical Research Programs, undermining progress in developing new treatments and improving patient outcomes. Contact your elected officials: zerocancer.quorum.us/campaign/SAV...

000

The PCCTC @thepcctc.bsky.social · 10/03/2025

CALL TO ACTION. Contact your elected officials and urge them to vote NO on a continuing resolution that includes a 57% cut to the Congressionally Directed Medical Research Program and its long-standing Prostate Cancer Research Program: zerocancer.quorum.us/campaign/SAV...

Image of Capitol Building with text reading, CALL TO ACTION: Oppose 57% Cut to Congressionally Directed Medical Research Programs. Vote NO on the FY25 Continuing Resolution. Contact your elected officials and urge them to vote NO on a continuing resolution that includes a 57% cut to the Congressionally Directed Medical Research Program and its long-standing Prostate Cancer Research Program.

010

The PCCTC @thepcctc.bsky.social · 10/02/2025

We are pleased to announce that science from seven Prostate Cancer Clinical Trials Consortium (PCCTC) studies will be presented at the 2025 ASCO Genitourinary Cancers Symposium later this week.

Science from seven Prostate Cancer Clinical Trials Consortium (PCCTC) studies will be presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, CA on February 13-15. ASCO GU features the latest high-impact science, multidisciplinary expertise, and evidence-based practices in GU cancer care. PCCTC investigators will share results from their innovative, hypothesis driven, multicenter studies, as well as summaries of trials in progress which will help shape the prostate cancer therapeutic landscape.

051

The PCCTC @thepcctc.bsky.social · 27/01/2025

Urology Practice publishes PHEN's peer-reviewed study co-authored by PCCTC CEO Jake Vinson: Black Men Not Being Asked to Participate in Prostate Cancer Clinical Trials www.auajournals.org/doi/epdf/10....

Cover page of manuscript titled Identification of Factors Affecting the Accrual of Black Males Into Prostate Cancer Clinical Trials in the United States

001

The PCCTC @thepcctc.bsky.social · 22/01/2025

The PCCTC’s work as a clinical study consortium and contract research organization (CRO) is led by our Guiding Principles www.pcctc.org/guidingprinc...

021

The PCCTC @thepcctc.bsky.social · 14/01/2025

Participating in the PCCTC-managed PROMISE Registry will add to our understanding of how genetic differences can affect patient outcomes, help family members understand their own risk of cancer, and guide discovery of new personalized treatments. To learn more visit www.prostatecancerpromise.org

011

The PCCTC @thepcctc.bsky.social · 23/12/2024

PCCTC investigators and colleagues collaborate on Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer (JCO Oncol Pract) pubmed.ncbi.nlm.nih.gov/39700441/

010

The PCCTC @thepcctc.bsky.social · 03/12/2024

DORA (NCT03574571) is the PCCTC-managed phase 3 trial of docetaxel vs. docetaxel and radium-223 for metastatic castration-resistant prostate cancer now accruing at 71 sites across the globe clinicaltrials.gov/study/NCT035...

030

The PCCTC @thepcctc.bsky.social · 25/11/2024

New webinar now available! The PCCTC, The Oncology Institute, and Trial Library recently partnered for insightful conversation titled “Decentralized Community-Engaged Recruitment to a Prostate Cancer Registry Study: docs.google.com/forms/d/e/1F...

040

The PCCTC @thepcctc.bsky.social · 20/11/2024

Dear Colleagues, the Prostate Cancer Clinical Trials Consortium (PCCTC) is now on BlueSky. We invite you to follow us at @thepcctc.bsky.social Thank you for supporting our mission!

051